vimarsana.com

Latest Breaking News On - தேசிய சங்கம் ஆஃப் பலகைகள் மருந்தகம் - Page 7 : vimarsana.com

Global alliance unites pharma pros to battle counterfeiting

Global alliance unites pharma pros to battle counterfeiting Fight the Fakes gathers manufacturers and other stakeholders to brainstorm on ways to combat falsified medicines and safeguard the world’s medicine supply. Pharmaceutical counterfeiting is a widespread, pervasive problem that impacts not only pharma companies, but anyone who finds themselves in need of medicines. The minds behind Fight the Fakes launched the organization to bring together industry colleagues to work toward ways to thwart counterfeiters wherever they may strike. Outsourcing-Pharma (OSP) recently spoke with Adam Aspinall (AA) chair of the Fight the Fakes Alliance, as well as senior director of access and product management for the Medicines for Malaria Venture about global counterfeiting, the group’s mission, accomplishments to date, and how individuals may join the organization in its work.

NABP Receives BBB Torch Award for Marketplace Ethics

NABP Receives BBB Torch Award for Marketplace Ethics MOUNT PROSPECT, IL, Dec. 14, 2020 (GLOBE NEWSWIRE) The National Association of Boards of Pharmacy ® (NABP ®) received the Better Business Bureau (BBB) of Chicago and Northern Illinois’s Torch Award for Marketplace Ethics on December 10, 2020. “The Torch Award is the most prestigious award the BBB can present to a business,” said Steve J. Bernas, president & CEO of the Better Business Bureau serving Chicago and Northern Illinois. “Torch Award winners demonstrate the highest ethical standards and trust with customers, business partners, and the communities in which they do business. Being a recipient of this award indicates the company not only believes in the high standards promoted by the BBB, but consistently demonstrates and integrates them into daily business practices.” This year marks the first year this award was granted to an organization in BBB’s new category for associations.

Pfizer, BioNTech COVID-19 vaccine gets emergency use authorization

Managing Editor The first vaccine to prevent COVID-19 has been cleared for use in the United States. The Food and Drug Administration on Saturday granted emergency use authorization to Pfizer and BioNTech’s COVID-19 vaccine for use in individuals 16 years old and older. The first shipments began leaving facilities on Sunday.  The FDA’s decision was based on data from its Phase 3 clinical study, whose results were published last week in the New England Journal of Medicine and which saw a 95% vaccine efficacy rate. The two companies continue to gather additional data and prepare a biologics license application for full approval from the FDA in 2021. 

Pharmacy Organizations Welcome FDA Authorization of COVID Vaccine: We Stand Ready to Serve

Share this article Share this article WASHINGTON, Dec. 11, 2020 /PRNewswire/  The leaders of 18 pharmacy organizations today issued the following statement following the Food and Drug Administration s approval of the first Emergency use Authorization for the COVID-19 vaccine. We heartily welcome the decision by the US Food and Drug Administration (FDA) to authorize the emergency use of the first COVID-19 vaccine, following the recommendation of the Vaccines and Related Biological Products Advisory Committee (VRBPAC). This is a historic moment in the nation s effort to end the pandemic. The pharmacy profession is ready to do its part as qualified, active participants in administering these vaccines in accordance with guidance issued by the FDA, CDC, HHS and state and local health departments, as well as increasing access for the American public to these important disease prevention tools.

© 2024 Vimarsana

vimarsana © 2020. All Rights Reserved.